Mazdutide vs Survodutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Mazdutide
4–4 mg
Survodutide
3.6–3.6 mg
Frequency
Mazdutide
Once daily
Survodutide
Once daily
Administration
Mazdutide
Subcutaneous injection
Survodutide
subcutaneous injection
Cycle length
Mazdutide
Ongoing/indefinite
Survodutide
Ongoing/indefinite
Onset speed
Mazdutide
Moderate (1-2 weeks)
Survodutide
Moderate (1-2 weeks)
Evidence level
Mazdutide
Strong human trials (Phase 3 or FDA approved)
Survodutide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Weight Loss
Blood Sugar Control
Metabolic Health
Weight Management
Compound specifications
Mazdutide
Molecular formula
C210H322N46O67
Molecular weight
4563.1 Da
Half-life
Approximately 8 days
Bioavailability
Subcutaneous bioavailability characteristic of acylated peptide analogs
CAS number
2259884-03-0
Survodutide
Molecular formula
C192H289N47O61
Molecular weight
4,231.6 Da
Half-life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
CAS number
2805997-46-8
Dosing compared
Mazdutide
Subcutaneous
Initial titration weeks
1.5 mg
Once weekly · Initial titration weeks
GLORY-1 Phase 3 starting dose; mazdutide was initiated at 1.5 mg once weekly and titrated stepwise toward the target maintenance dose to limit GI effects [6].
Weeks 32-48
4 mg
Once weekly · Maintenance (32-48 weeks in trial)
GLORY-1 Phase 3 maintenance dose; produced about 11-12% mean body-weight reduction. Approved in China at this strength for weight management [6].
Weeks 32-48
6 mg
Once weekly · Maintenance (32-48 weeks in trial)
GLORY-1 Phase 3 higher maintenance dose; produced about 13-15% mean body-weight reduction. Approved in China at this strength alongside the 4 mg dose [6].
Survodutide
Subcutaneous
Initiation, part of a 20-week up-titration
0.6 mg
Once weekly · Initiation, part of a 20-week up-titration
Phase 2 starting dose; gradual escalation reduces GI side effects [1].
26-week maintenance after escalation
3.6 mg
Once weekly · 26-week maintenance after escalation
Maintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
26-week maintenance after escalation
4.8 mg
Once weekly · 26-week maintenance after escalation
Highest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].
Best suited for
Mazdutide
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. [6][7] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. [1][15] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. [6][18] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. [4][5] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide
Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Mazdutide
Common
- Nausea
- Diarrhea
- Decreased Appetite
Uncommon
- Vomiting
- Injection Site Reactions
Serious
- Acute Pancreatitis
- Acute Cholecystitis and Biliary Disease
- Severe Nausea and Gastrointestinal Intolerance
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Safety & evidence
Mazdutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Mazdutide (Roche/Carmot GLP-1/GCG/GIP triple agonist) completed Phase Ib with generally favorable safety profile but dose-limiting gastrointestinal side effects. [11] Nausea/vomiting occur in 40-50% of subjects at higher doses; [7][12] weight loss averaging 12-18% observed. [6][7] Pancreatitis risk monitoring required; [9][10] calcitonin elevation consistent with GCG activation. Heart rate increases 5-8 bpm; no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to mazdutide or any formulation excipients
- History of severe pancreatitis
- Severe renal impairment (eGFR <15 mL/min) without clinical data
Survodutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (nausea up to 75% at highest doses, diarrhea, vomiting) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to survodutide or excipients
- History of pancreatitis (caution advised with GLP-1 receptor agonists)
Which is right for you?
Choose Mazdutide if...
- Individuals seeking substantial weight loss exceeding 15% body weight
- Adults with type 2 diabetes requiring superior glycemic management
- Patients with obesity-related metabolic comorbidities
- Those seeking dual-mechanism metabolic therapy
Choose Survodutide if...
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement